OUR PURPOSE PIONEERING SCIENCE PATIENTS OUR PEOPLE ENVIRONMENT COMMUNITY REPORTING 41 ADVANCING HEALTH ACCESS AND EQUITY BIOGEN 2021 YEAR IN REVIEW HIGHLIGHTS of Biogen’s commitments in Governance & Access 1 Biogen is committed to responsible business practices, as outlined in our Code of Business Conduct and other policies. Biogen’s Board of Directors governs Biogen’s processes for maintaining the integrity of the company, including Environmental, Social and Governance (ESG) issues, following the company’s Corporate Governance Principles . Biogen’s corporate strategy includes building on our priorities for health equity and access. Our Early Access Principles + Program Overview is available here . Visit our Access page for a description of Biogen’s approach to off-label use. 2 Biogen staff are incented to advance the company strategy, which includes health equity and access as priorities. 3 Biogen is committed to Ethical Marketing and to disclosure following the GRI, SASB and Stakeholder Capitalism metrics. 4 Biogen’s ethics and compliance policies and programs and Code of Business Conduct are designed, in part, to prevent corrupt or non-compliant activity in operations. The company also has a Responsible Supplier Program, including an evaluation process to identify any potential at-risk suppliers that could warrant further evaluation. ACCESS TO MEDICINE R e s e a r c h & D e v e l o p m e n t STAKEHOLDER PRIORITIES Product Development, Access Planning and R&D Capacity Building Underlines any clear benefit to lower- and middle-income countries: accessibility and availability are crucial Contributions to local R&D capacity are important re: empowering local researchers to address population needs 1 2 3 HIGHLIGHTS of Biogen’s commitments in Research & Development 1 In 2020, Biogen launched three Health Equity Advisory Boards – access, clinical trials and policies – to better understand patient needs to improve access to our therapies; ensure clinical trials reflect the target population; and consider policies that support access and equity. We comply with government regulations and engage with regulatory agencies and others to ensure that new and innovative therapies are commercially available to the patients who need them. 2 SPINRAZA is approved in 65 countries, including low- and middle-income countries. In markets with low GDP per capita, we have engaged with innovative agreements to meet each market’s individual needs. It is our strong belief that the decision to treat should be between the physician and the family, without budget concerns. Our policy to promote access to SPINRAZA will help inform our approach to our broader portfolio of therapies. 3 Biogen has a range of active initiatives to help foster local R&D capacity in diverse local populations. For example, we collaborate with Morehouse School of Medicine on a fellowship program which engages M.D. and Ph.D. students, aiming to advance health equity and improve patient experiences. In 2016, Biogen helped create The Partnership, Inc.’s BioDiversity Fellows Program, which nurtures the potential leadership of mid-career professionals who are underrepresented in the life sciences industry. We also sponsor the Golden Ticket Award, a competitive process seeking to identify rising startup companies in the field of neuroscience. Each Biogen-LabCentral Golden Ticket includes up to one year of bench space for one scientist and the benefits of LabCentral’s shared infrastructure and services at no cost to the contest winner. G o v e r n a n c e o f A c c e s s STAKEHOLDER PRIORITIES Governance, strategy and responsible business practices Staff incentivization toward fostering access to medicine Ethical marketing and disclosure policies Prevention of corrupt or non-compliant activity in operations 1 2 3 4